(Reuters) – AstraZeneca said on Friday its unit Alexion has agreed to buy a portfolio of U.S. drugmaker Pfizer’s early-stage rare disease gene therapy for up to $1 billion, plus royalties on sales.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Nivedita Bhattacharjee)
